References

Abaji, R., & Krajinovic, M. (2017). Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response. Pharmacogenomics and Personalized Medicine, 143-156.

Agyeman, A. A., & Ofori-Asenso, R. (2015). Perspective: Does personalized medicine hold the future for medicine?. Journal of pharmacy & bioallied sciences, 7(3), 239.

Belle, D. J., & Singh, H. (2018). Genetic factors in drug metabolism. American family physician, 77(11), 1553-1560.

Berm, E. J., Looff, M. D., Wilffert, B., Boersma, C., Annemans, L., Vegter, S., ... & Postma, M. J. (2016). Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PloS one, 11(1), e0146262.

Blazer, D. G., & Hernandez, L. M. (Eds.). (2016). Genes, behavior, and the social environment: Moving beyond the nature/nurture debate.

Bradford, K., & Shih, D. Q. (2011). Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World journal of gastroenterology: WJG, 17(37), 4166.

Bullers, K. (2016). Merck manuals. Journal of the Medical Library Association: JMLA, 104(4), 369.

Chang, M. T., McCarthy, J. J., & Shin, J. (2015). Clinical application of pharmacogenetics: focusing on practical issues. Pharmacogenomics, 16(15), 1733-1741.

Cully, M. (2015). Genetic information adds supporting weight. Nature Reviews Drug Discovery, 14(8), 525-525.

Dean, L. (2012). Thioguanine therapy and TPMT genotype. Medical Genetics Summaries, Pratt V, McLeod H, Dean L, Malheiro A, and Rubinstein W, eds.(National Center for Biotechnology Information (US)).[Google Scholar].

Emily Guo, X., Ngo, B., Sandaldjian Modrek, A., & Lee, W. H. (2014). Targeting tumor suppressor networks for cancer therapeutics. Current drug targets, 15(1), 2-16.

Etienne-Grimaldi, M. C., Boyer, J. C., Thomas, F., Quaranta, S., Picard, N., Loriot, M. A., ... & Collective work by the Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer) and the French Réseau National de Pharmacogénétique Hospitalière (RNPGx). (2015). UGT 1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundamental & Clinical Pharmacology, 29(3), 219-237.

Fiers, W., Contreras, R., Duerinck, F., Haegeman, G., Iserentant, D., Merregaert, J., ... & Ysebaert, M. (2000). Complete nucleotide sequence of bacteriophage MS2 RNA: primary and secondary structure of the replicase gene. Nature, 260(5551), 500-507.

Filipski, K. K., Mechanic, L. E., Long, R., & Freedman, A. N. (2014). Pharmacogenomics in oncology care. Frontiers in genetics, 5, 73.

Flockhart, D. A., O'Kane, D., Williams, M. S., Watson, M. S., Gage, B., Gandolfi, R., ... & Veenstra, D. (2008). Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genetics in Medicine, 10(2), 139-150.

Fujita, K. I., Kubota, Y., Ishida, H., & Sasaki, Y. (2015). Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World journal of gastroenterology, 21(43), 12234.

Furuta, T., Sugimoto, M., Shirai, N., & Ishizaki, T. (2017). CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.

Goodsaid, F., & Frueh, F. W. (2017). Implementing the US FDA guidance on pharmacogenomic data submissions. Environmental and molecular mutagenesis, 48(5), 354-358.

H Lee, N. (2010). Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 10(8), 583-592.

Hood, L., & Rowen, L. (2013). The human genome project: big science transforms biology and medicine. Genome Med 5 (9): 79.

Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British journal of pharmacology, 162(6), 1239-1249.

Karazniewicz-Lada, M., Danielak, D., & Glówka, F. (2012). Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expert opinion on pharmacotherapy, 13(5), 663-683.

Karczewski, K. J., Daneshjou, R., & Altman, R. B. (2012). Chapter 7: pharmacogenomics. PLoS computational biology, 8(12), e1002817.

Koscielny, G., An, P., Carvalho-Silva, D., Cham, J. A., Fumis, L., Gasparyan, R., ... & Dunham, I. (2017). Open Targets: a platform for therapeutic target identification and validation. Nucleic acids research, 45(D1), D985-D994.

Kraljevic, S., Stambrook, P. J., & Pavelic, K. (2004). Accelerating drug discovery: Although the evolution of ‘-omics’ methodologies is still in its infancy, both the pharmaceutical industry and patients could benefit from their implementation in the drug development process. EMBO reports, 5(9), 837-842.

Kuznetsov, V., Lee, H. K., Maurer-Stroh, S., Molnár, M. J., Pongor, S., Eisenhaber, B., & Eisenhaber, F. (2013). How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health. Health Information Science and Systems, 1, 1-18.

Lala, A., Berger, J. S., Sharma, G., Hochman, J. S., Braithwaite, R. S., & Ladapo, J. A. (2013). Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. Journal of thrombosis and haemostasis, 11(1), 81-91.

Lavezzari, G., & Womack, A. W. (2016). Industry perspectives on biomarker qualification. Clinical Pharmacology & Therapeutics, 99(2), 208-213.

Lee, H. H., & Ho, R. H. (2017). Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). British journal of clinical pharmacology, 83(6), 1176-1184.

Limdi, N. A., & Veenstra, D. L. (2018). Warfarin pharmacogenetics. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 28(9), 1084-1097.

Luo, Y., Zhao, X., Zhou, J., Yang, J., Zhang, Y., Kuang, W., ... & Zeng, J. (2017). A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information. Nature communications, 8(1), 573.

Ma, T. K., Lam, Y. Y., Tan, V. P., & Yan, B. P. (2011). Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?. British journal of clinical pharmacology, 72(4), 697-706.

Mestan, K. K., Ilkhanoff, L., Mouli, S., & Lin, S. (2011). Genomic sequencing in clinical trials. Journal of Translational Medicine, 9(1), 1-10.

Mohelnikova-Duchonova, B., Melichar, B., & Soucek, P. (2014). FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy. World journal of gastroenterology: WJG, 20(30), 10316.

Novelli, G., Ciccacci, C., Borgiani, P., Amati, M. P., & Abadie, E. (2018). Genetic tests and genomic biomarkers: regulation, qualification and validation. Clinical cases in mineral and bone metabolism, 5(2), 149.

Pritchard, D. E., Moeckel, F., Villa, M. S., Housman, L. T., McCarty, C. A., & McLeod, H. L. (2017). Strategies for integrating personalized medicine into healthcare practice. Personalized medicine, 14(2), 141-152.

Rasmussen-Torvik, L. J., Stallings, S. C., Gordon, A. S., Almoguera, B., Basford, M. A., Bielinski, S. J., ... & Denny, J. C. (2014). Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clinical Pharmacology & Therapeutics, 96(4), 482-489.

Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature, 526(7573), 343-350.

Roses, A. D. (2000). Pharmacogenetics and the practice of medicine. Nature, 405(6788), 857-865.

Satoh, J. I., Yanaizu, M., Tosaki, Y., Sakai, K., & Kino, Y. (2016). Targeted sequencing approach to identify genetic mutations in Nasu-Hakola disease. Intractable & Rare Diseases Research, 5(4), 269-274.

Schuck, R. N., & Grillo, J. A. (2016). Pharmacogenomic biomarkers: an FDA perspective on utilization in biological product labeling. The AAPS journal, 18, 573-577.

Scott, S. A. (2011). Personalizing medicine with clinical pharmacogenetics. Genetics in medicine, 13(12), 987-995.

Sheweita, S. A. (2000). Drug-metabolizing enzymes mechanisms and functions. Current drug metabolism, 1(2), 107-132.

Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014). Computational methods in drug discovery. Pharmacological reviews, 66(1), 334-395.

Spoonamore, K. G., & Johnson, N. M. (2016). Who pays? Coverage challenges for cardiovascular genetic testing in US patients. Frontiers in Cardiovascular Medicine, 3, 14.

Teh, L. K., Hashim, H., Zakaria, Z. A., & Salleh, M. Z. (2012). Polymorphisms of UGT1A1* 6, UGT1A1* 27 & UGT1A1* 28 in three major ethnic groups from Malaysia. The Indian journal of medical research, 136(2), 249.

Thomsen, S. K., & Gloyn, A. L. (2017). Human genetics as a model for target validation: finding new therapies for diabetes. Diabetologia, 60(6), 960-970.

Ventola, C. L. (2013). The role of pharmacogenomic biomarkers in predicting and improving drug response: part 2: challenges impeding clinical implementation. Pharmacy and therapeutics, 38(10), 624.

Verbelen, M., Weale, M. E., & Lewis, C. M. (2017). Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?. The pharmacogenomics journal, 17(5), 395-402.

Vogenberg, F. R., Barash, C. I., & Pursel, M. (2010). Personalized medicine: part 1: evolution and development into theranostics. Pharmacy and Therapeutics, 35(10), 560.

Wang, Y., Probin, V., & Zhou, D. (2016). Cancer therapy-induced residual bone marrow injury: mechanisms of induction and implication for therapy. Current cancer therapy reviews, 2(3), 271-279.

Wu, J., Li, Y., & Jiang, R. (2014). Integrating multiple genomic data to predict disease-causing nonsynonymous single nucleotide variants in exome sequencing studies. PLoS genetics, 10(3), e1004237.